WASHINGTON, DC (January 22, 2019) — The Association for Accessible Medicines (AAM) is pleased to announce that three new members have joined its Biosimilars Council:
- Accord Healthcare Inc.
- Fresenius Kabi USA, LLC
- Sagent Pharmaceuticals, Inc.
FDA-approved biosimilars have been estimated to have the potential to save patients and the health care system anywhere from $54 to $250 billion over their first 10 years on the market. Indeed, although the U.S. biosimilars market is still in its nascency, currently marketed biosimilars are competitively priced 40 percent lower on average than their brand reference products in terms of list price.
A complete list of Biosimilars Council Members can be found here.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.